SCHEMBL31023980

SCHEMBL31023980

O=Cn1nnc2cc(Cl)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.50
LIMK1 P53667 1/20 0.50
MAPK14 Q16539 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
KCNMA1 Q12791 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.39
KMO O15229 1/20 0.38
CUL4A Q13619 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MGAM O43451 2/20 0.36
AMY1A P0DUB6 2/20 0.36
GAA P10253 2/20 0.36
SI P14410 2/20 0.36
MGAM2 Q2M2H8 2/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023751 0.79 KCNMA1 (0.44) KCNMA1RAB9AKDM4EMEN1KMT2A
SCHEMBL11264259 0.75 CHEK1 (0.53) CHEK1LIMK1MAPK14CLK4KCNMA1
SCHEMBL221980 0.73 RAB9A (0.53) KCNMA1L3MBTL1NPC1RAB9AKMT2A
SCHEMBL30586926 0.73 RAB9A (0.53) KCNMA1L3MBTL1NPC1RAB9AKMT2A
SCHEMBL3676899 0.72 PKM (0.56) CHEK1LIMK1MAPK14CLK4KCNMA1
SCHEMBL3278710 0.72 PKM (0.56) CHEK1LIMK1MAPK14CLK4KCNMA1
Water SCHEMBL27351048 0.72 RAB9A (0.51) KCNMA1L3MBTL1NPC1RAB9AKMT2A
SCHEMBL1150909 0.72 CHEK1 (0.50) CHEK1LIMK1MAPK14CLK4KCNMA1
SCHEMBL1133392 0.72 RAB9A (0.56) CHEK1LIMK1MAPK14CLK4KCNMA1
SCHEMBL11053779 0.70 CHEK1 (0.49) CHEK1LIMK1MAPK14CLK4KCNMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US claimed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL CHEK1 3639/4885LIMK1 1226/4885MAPK14 2073/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL CHEK1 3639/4885LIMK1 1226/4885MAPK14 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.